Co-administration of FGF-21 and GLP-1 to treat diabetes and lower blood glucose

• US 8,557,769 B2
• Filed: 06/27/2012
• Issued: 10/15/2013
• Est. Priority Date: 08/03/2007
• Status: Expired due to Fees

• Current Assignee: Eli Lilly and Company
• Original Assignee: Eli Lilly and Company
• Inventors: Coskun, Tamer, Glaesner, Wolfgang
• Primary Examiner(s): Saoud, Christine J
• Application Number:
  US13/534,322
• Publication Number:
  US 20120264683A1
• Time in Patent Office: 475 Days
• Field of Search: None
• US Class Current: 514/9.1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/1825 Fibroblast growth factor [FGF]
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention provides methods of lowering body weight by administering an FGF-21 compound in combination with a GLP-1 compound. In addition, the present invention also provides methods to treat obesity by administering an FGF-21 compound in combination with a GLP-1 compound. The present invention also discloses combinations useful in the methods of the present invention.

Claims

1. A method of treating diabetes comprising administering an FGF-21 compound in combination with a GLP-1 compound, wherein the FGF-21 compound has the amino acid sequence of SEQ ID NO:

2, and wherein the GLP-1 compound has the amino acid sequence of SEQ ID NO;

19.

2. A method of lowering blood glucose levels comprising administering an FGF-21 compound in combination with a GLP-1 compound, wherein the FGF-21 compound has the amino acid sequence of SEQ ID NO:

2, and wherein the GLP-1 compound has the amino acid sequence of SEQ ID NO;

19.